IBEX

Ibex is the pioneer in applying computational pathology to cancer diagnostics. Based out of Tel Aviv, Israel, the company's machine learning experts, data scientists and pathologists use artificial intelligence (AI) to develop clinical grade algorithms that can detect prostate cancer as accurately as a human pathologist.

Pathologists are challenged to provide accurate and timely analysis as the number of tests increases year-over-year.  In an effort to improve their workflow, pathology labs are starting to adopt digital technologies, including AI-based analysis of biopsies.  Ibex's algorithms analyzes biopsy images, detects cancerous cells, grades them and can also detect other clinically significant features.  The analysis is presented to pathologists either before or after reviewing the case, helping them in reducing error rates and improving operational efficiency by reducing the average time spent on a case.

Deployed in Israel, Europe and the United States, Ibex's solution is the first-ever AI-based cancer diagnosis solution in routine clinical use in a pathology lab and has already demonstrated success in detecting missed cancer cases.  The first application Ibex released is for prostate and breast and it works on expanding to additional tissues.  Ibex recently raised $15 million from prominent VC funds and corporate investors.


IBEX


Address: 
97 Rokach Blvd
Tel Aviv-Yafo, Israel
6153101